MX2017006959A - Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. - Google Patents

Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable.

Info

Publication number
MX2017006959A
MX2017006959A MX2017006959A MX2017006959A MX2017006959A MX 2017006959 A MX2017006959 A MX 2017006959A MX 2017006959 A MX2017006959 A MX 2017006959A MX 2017006959 A MX2017006959 A MX 2017006959A MX 2017006959 A MX2017006959 A MX 2017006959A
Authority
MX
Mexico
Prior art keywords
vedolizumab
methods
bowel disease
establishing
dosing regimen
Prior art date
Application number
MX2017006959A
Other languages
English (en)
Inventor
Singh Sharat
Jain Anjali
Kondragunta Venkateswarlu
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017006959A publication Critical patent/MX2017006959A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona métodos para predecir si es probable que un individuo que tenga enfermedad inflamatoria intestinal (IBD) responda al tratamiento con vedolizumab. También se proporcionan métodos para predecir si un individuo con IBD tal como enfermedad de Crohn o colitis ulcerosa desarrollará autoanticuerpos contra vedolizumab. La presente invención también proporciona un régimen de tratamiento para un paciente de IBD que incluye medir el nivel de uno o más marcadores predictivos de respuesta al vedolizumab antes de administrar el fármaco anti-integrina a4ß7.
MX2017006959A 2014-12-02 2015-12-02 Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. MX2017006959A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086549P 2014-12-02 2014-12-02
US201562157903P 2015-05-06 2015-05-06
PCT/IB2015/059303 WO2016088068A1 (en) 2014-12-02 2015-12-02 Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease

Publications (1)

Publication Number Publication Date
MX2017006959A true MX2017006959A (es) 2017-08-10

Family

ID=54849673

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006959A MX2017006959A (es) 2014-12-02 2015-12-02 Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable.

Country Status (7)

Country Link
US (1) US10324088B2 (es)
EP (1) EP3227685A1 (es)
JP (1) JP2018504584A (es)
CA (1) CA2969326A1 (es)
HK (1) HK1244881A1 (es)
MX (1) MX2017006959A (es)
WO (1) WO2016088068A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018349287A1 (en) * 2017-10-10 2020-05-07 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
WO2019178546A1 (en) 2018-03-16 2019-09-19 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
EP3543692A1 (en) * 2018-03-22 2019-09-25 Friedrich-Alexander-Universität Erlangen-Nürnberg Adhesion assay
WO2020226498A1 (en) 2019-05-07 2020-11-12 Rijksuniversiteit Groningen Biomarker, kit and method for predicting clinical responsiveness to therapy with an agent that targets alpha4beta7 integrin.
AU2020308906A1 (en) 2019-06-27 2022-02-03 Scipher Medicine Corporation Developing classifiers for stratifying patients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0615129B1 (en) 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
EP1687447A4 (en) 2003-11-03 2008-04-02 Univ Duke METHODS FOR IDENTIFYING INDIVIDUALS WITH PERIOPERATIVE RISK OF BLEEDING, RENAL DYSFUNCTION OR ICTUS
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
CN102016581B (zh) 2008-02-25 2014-07-30 雀巢产品技术援助有限公司 用抗体阵列选择乳腺癌治疗药物
EP2279004B1 (en) * 2008-05-16 2015-01-14 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
NZ599456A (en) 2009-10-26 2014-06-27 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
EP2632492B1 (en) * 2010-10-25 2017-10-04 Biogen MA Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
WO2012154987A1 (en) * 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
MX352274B (es) * 2011-10-21 2017-11-16 Nestec Sa Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.
US20140051184A1 (en) 2012-08-15 2014-02-20 Nestec S.A. Mobility shift assays for detecting anti-tnf alpha drugs and autoantibodies thereto
RU2015112024A (ru) * 2012-10-05 2016-11-27 Дженентек, Инк. Способы диагностики и лечения воспалительного заболевания кишечника
WO2014160753A1 (en) * 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
EP3004068A2 (en) * 2013-05-24 2016-04-13 Nestec S.A. Pathway specific assays for predicting irritable bowel syndrome diagnosis

Also Published As

Publication number Publication date
US10324088B2 (en) 2019-06-18
EP3227685A1 (en) 2017-10-11
JP2018504584A (ja) 2018-02-15
CA2969326A1 (en) 2016-06-09
WO2016088068A1 (en) 2016-06-09
US20170254806A1 (en) 2017-09-07
HK1244881A1 (zh) 2018-08-17

Similar Documents

Publication Publication Date Title
MX2016002879A (es) Sistemas, dispositivos y metodos para la terapia anti-tl1a.
PH12016502167A1 (en) Hdl theraphy markers
MX2017006959A (es) Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable.
MY194686A (en) Detection of chromosome interactions
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
FR3016705B1 (fr) Systeme de compensation visuelle et dispositif binoculaire d'optometrie
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
IL246917B (en) Biomarker and early diagnosis methods for Alzheimer's disease
MX2017013383A (es) Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
MX2016012282A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
MY191324A (en) Neutralizing anti-tl1a monoclonal antibodies
NZ707035A (en) Gene signatures of inflammatory disorders that relate to the liver
MX2017004742A (es) Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos.
MA40354A (fr) Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
MY197061A (en) Improved 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
MX2023006097A (es) Metodos in vitro para la deteccion de mutaciones en neoplasmas intracraneales.
FR3017703B1 (fr) Procede et systeme de determination de la compatibilite d'un guidage angulaire avec une approche
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.
EA201790609A1 (ru) Макроциклические ингибиторы rip2-киназы
MX2018009112A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico.
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants